Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The New Digital Platform for Ketamine Treatments

Stockhouse Editorial
3 Comments| April 25, 2022

{{labelSign}}  Favorites
{{errorMessage}}

Engaged in drug development of psychedelic compounds, NeonMind Biosciences Inc. (CSE: NEON, Forum) recently announced that it had advanced its strategy to streamline access to treatments at its specialty mental health clinics with Thrive Health in preparation of opening its inaugural clinic located in Mississauga, Ontario.

NeonMind will be working with digital care platform Thrive Health, which is used by many hospitals and clinics and selected as the official partner by Health Canada in the development of the Canada COVID-19 app.

The company’s President & CEO, Rob Tessarol said in a release on this news he is seeing greater institutional coverage for IV-Ket treatment which he called a testament to the treatment's value to the health system.

“Institutional reimbursement validates the treatment in Canada, and we are primed for increased demand for this treatment.”

An integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, NeonMind recently advanced its strategy to enhance access to treatments at its specialty mental health clinics with Impetus Digital and its large portfolio of cutting-edge, life science-specific online collaboration tools.

This builds upon recent news, where NeonMind plans to launch 10 specialty mental health clinics over the next 3 years through alliances with SRx Health Solutions and BioScript Solutions, leading Canadian specialty healthcare services and medical treatment providers.

CEO Tessarolo added that by partnering with SRx Health Solutions and BioScript, the company can can leverage its established clinic network and operational excellence in specialty medical treatments to introduce its mental health treatments in an expedient and capital efficient manner and work with an infrastructure that enables scaling.

“With very little upfront costs for each location, we expect to be able to open NeonMind clinics in at least 10 new communities over the next few years and are pleased to offer this referral service to medical doctors and their patients who recognize the benefits of IV-Ket and neurostimulation but are not set up to deliver the treatments in their own clinics.”

NEON stock is up more than 10% on Monday, trading at $0.16.


FULL DISCLOSURE: NeonMind Biosciences Inc. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today